Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Radioligand therapy (RLT) using Lu-177 labelled PSMA is a promising new therapeutic approach
to treat metastatic prostate cancer. This tumor-specific treatment is directed against
prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.
In the last few years, several lutetium-177 (177Lu, β emitter) labeled PSMA ligands have been
developed and are currently applied to treat metastatic castrate resistant prostate cancer
(mCRPC) patients. However, there are no prospective studies published so far using this
treatment approach in hormone sensitive setting. In this pilot study patients with hormone
sensitive prostate cancer who did not undergo hormonal treatment will be treated with Lu-177
PSMA-617.